# Xvivo Q3 Earnings Report

> Xvivo Perfusion AB reports 32% organic growth in Q3 2026 earnings.
- Title: Xvivo Q3 Earnings Report · Seekingalpha | Shortify
- Summary: Xvivo Perfusion AB reports 32% organic growth in Q3 2026 earnings. Xvivo Perfusion AB achieved 32% organic growth in Q3 2026 with sales in line with prior…
- Keywords: xvivo perfusion ab, q3 2026, earnings call, organic growth, ebitda, cash flow, money, business, Xvivo, Earnings, Report, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4956637-xvivo-perfusion-ab-publ-xvipy-q3-2026-earnings-call-transcript
- Author: SA Transcripts
- Published: 2026-10-22T19:47:19+00:00
- Read time: 1 min
- Topics: xvivo perfusion ab, q3 2026, earnings call, organic growth, ebitda, cash flow, money, business
## Q3 2026 Results
Xvivo Perfusion AB reported 32% organic growth in Q3 2026 with sales in line with the first half of the year.
## Financial Performance
EBITDA remained strong, supporting healthy operating cash flow with total cash flow close to neutral for the fourth consecutive quarter.
## Market Trends
Thoracic division continued strong performance across North America and Europe, supported by positive market trends from the end of last year.
## Key takeaway

Xvivo Perfusion AB achieved 32% organic growth in Q3 2026 with sales in line with prior half-year performance.